Targeting CSF-1R can reduce GB-associated macrophages in the tumor microenvironment and promote GB-associated macrophage repolarization, limiting tumor development, avoiding the recurrence of glioblastoma and promoting cytotoxic T-cell activation (Vegliante et al., 2022). The gene discussed is CSF1R; the disease is neoplasm.